January 10, 2017

WASHINGTON, D.C./MINNEAPOLIS, MN - January 11, 2017 -The COPD Foundation-sponsored COPD Biomarker Qualification Consortium (CBQC) today announced that it has partnered with the Bio-Techne Corporation, a manufacturer of biotechnology products for life science research and diagnostics. The partnership was established to evaluate the suitability of a soluble form of receptor for advanced glycation end products (sRAGE) as a predictive biomarker to support subject selection for clinical trials in emphysema. Increasing evidence suggests that serum sRAGE could serve as an indicator of the presence and/or progression of emphysema, a form of chronic obstructive disease (COPD). A validated commercial assay or test for sRAGE does not currently exist. The COPD Foundation, along with its partners in the CBQC and Bio-Techne, will be collaborating with a working group of industry and academic affiliates on the initiative.

December 09, 2016

WASHINGTON, D.C. - December 9, 2016 - The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), hosted its 2016 annual Air Affair Benefit, Thursday, Dec. 8, 2016, at the American Museum of Natural History in New York City. Dr. Byron Thomashow chaired the event as the Foundation paid tribute to a special group of individuals and organizations who were recognized for their contributions to the COPD community over the past year.

November 14, 2016

WASHINGTON, D.C. - November 14, 2016 - The COPD Foundation, a non-profit organization dedicated to finding a cure for chronic obstructive pulmonary disease (COPD), today brings supporters the ability to donate with Apple Pay. COPD is the third leading cause of death in the U.S. and affects 30 million Americans. The progressive lung disease is characterized by increased breathlessness, coughing, and wheezing.

The COPD Foundation relies on the support of its membership to implement its research, education, and advocacy initiatives. Apple Pay will allow COPD Foundation supporters with the option of a more efficient and secure online financial transaction, making it easier for members to help the organization’s mission to help those affected by COPD.

November 08, 2016

MADISON, WI - Nov. 8, 2016 - Propeller Health, the leading digital solution for respiratory medicine, today announced U.S. Food and Drug Administration 510(k) clearance to market its Propeller platform for use with GSK's Ellipta® inhaler, the pharmaceutical company's innovative, patented, dry powder inhaler (DPI). The sensor for the Ellipta inhaler was built and cleared as part of a development agreement and R&D collaboration between Propeller and GSK that was announced on December 1, 2015.

November 01, 2016

WASHINGTON, D.C. - November 1, 2016 - The COPD Foundation is pleased to celebrate COPD Awareness Month, an internationally recognized event held annually in November to enhance awareness of chronic obstructive pulmonary disease (COPD). Throughout the month, the COPD Foundation will partner with respiratory health organizations to host various online and in-person activities that will allow COPD community members to rally, inform, and support one another. COPD is a progressive lung disease with symptoms that include shortness of breath, wheezing, and cough. It is affects 300 million individuals worldwide and 30 million in the United States.

Key statistics about COPD include:

  • Every four minutes, someone in the U.S. dies of COPD
  • COPD causes 285,000 emergency hospitalizations annually in the U.S.
  • Approximately one in five Americans over the age of 45 lives with COPD

September 07, 2016

NEW ORLEANS - September 7, 2016 - New Orleans-area residents who suffer from chronic obstructive pulmonary disease (COPD) will soon breathe easier thanks to a partnership with the Tulane University School of Medicine and the Dorney-Koppel Foundation.

The Grace Anne Dorney Pulmonary and Cardiac Rehabilitation Center at Tulane Medical Center’s downtown campus is named after the wife of senior CBS Sunday Morning contributor and former Nightline anchor Ted Koppel. More importantly, though, Dorney-Koppel is president of the COPD Foundation and a longtime advocate for sufferers of chronic breathing conditions.

“Not being able to catch your breath – and the fear that your next breath might not be coming – is like drowning. Nothing is more frightening,” said Dorney-Koppel, who became a national spokesperson for COPD patients after being diagnosed with the disease herself more than 15 years ago. “Pulmonary rehabilitation is a breathing program based on the highest level of scientific evidence, and it can improve patient’s lives.

July 26, 2016

WASHINGTON, D.C. - July 26, 2017 - A team of patient and stakeholder partners and investigators from 20 Patient-Powered Research Networks (PPRNs) that comprise PCORnet will take part in a $4 million research project, Healthy Mind Healthy You, to determine the optimal type and frequency of mindfulness-based treatment for managing stress. This project will be under the leadership of MoodNetwork, an online network for patients with bipolar disorder and depression. MoodNetwork, based at Massachusetts General Hospital (MGH), is one of 20 PCORI-funded Patient-Powered Research Networks (PPRNs) participating in this study, which will also demonstrate the capabilities of PCORnet, the National Patient-Centered Clinical Research Network.

An ambitious initiative funded by the Patient-Centered Outcomes Research Institute (PCORI), PCORnet is accelerating the nation’s ability to conduct patient-centered clinical research more efficiently by using health information shared by patients and other clinical data. PPRNs, which are collaborations among patients, other stakeholders, and research partners who share an interest in advancing patient-centered research, comprise 20 of the 33 networks that together make up PCORnet.

June 15, 2016

WASHINGTON, D.C. – June 15, 2016 – The COPD Foundation today released a video animation, “A Child’s Eye,” to promote awareness and education about chronic obstructive pulmonary disease (COPD), a spectrum of inflammatory lung diseases that include chronic bronchitis and emphysema. Patients with COPD experience chronic respiratory symptoms such as difficulty breathing, wheezing, and coughing. Approximately 300 million people worldwide are affected by COPD. The video animation was developed by Make Believe Studios, an in-house creative studio that specializes in bringing stories to life through film, animation and digital output.

“A Child's Eye” is a short animated film commissioned by Novartis in collaboration with the COPD Foundation. It is inspired by real life stories from patients around the world and demonstrates the effects of the disease on patients’ loved ones, including caregivers, friends, and family. “A Child’s Eye” depicts the daily struggles of life with COPD from the perspective of a child whose beloved grandparent lives with the disease. Upon being introduced to COPD360social.org, a unique social networking website for individuals whose lives are affected by COPD, the child’s family is provided with educational resources and access to a worldwide community. By showing the meaningful impact lifestyle changes and treatment can have through the perspective of ‘Jonny’ (a patient’s grandchild), the video touches upon a central insight for people who live with COPD.

May 25, 2016

WASHINGTON, D.C. - May 25, 2016 - The U.S. Food and Drug Administration (FDA) has issued an updated draft guidance for industry to assist in the design of a clinical development programs for new COPD drug and biological products. The draft guidance, “Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment,” revises the 2007 version by adding information specific to the use of the St. George’s Respiratory Questionnaire (SGRQ) as a potential co-primary endpoint in clinical trials of COPD products. The SGRQ is a patient-reported health status questionnaire that has been used extensively since it was first published over 20 years ago. The COPD Foundation, along with its partners in the COPD Biomarker Qualification Consortium (CBQC) - AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Novartis, Pfizer, and many academic members - has long advocated for the broader recognition of the SGRQ as an important endpoint in the development of new drugs to treat COPD since it measures the impact of the disease on health related quality of life from a patient perspective.

May 19, 2016

WASHINGTON, D.C. - May 19, 2016 - The CT Lung Cancer Screening Protocol Challenge, the first crowd-sourced and ultra-low cost challenge of its kind, was launched by the COPD Foundation and its advisory committee to help the lung cancer and COPD imaging research communities determine the best CT scanners and protocols for detecting lung nodules and areas of the lungs that have been damaged due to emphysema. These clinical imaging tasks require high levels of CT scanner image quality and are essential to delivering high performance CT lung cancer and COPD screening.

All global lung cancer and COPD imaging clinical sites are invited to participate. The data submission phase for this first challenge ends on May 31, 2016 and initial findings will be released on June 13, 2016 at the Quantitative Imaging Workshop XIII. The data acquired from this challenge and free CT image quality service will assist the radiological community in developing and setting new standards for lung cancer and COPD quantitative imaging.

Page 1 of 24First   Previous   [1]  2  3  4  5  6  7  8  9  10  Next   Last   

Join Us on COPD360social

Sign In to Participate
Or register to become a member

Search Press Releases